Biocryst Pharmaceuticals Stock Annual Yield

BCRX Stock

USD 7.54 0.01 0.13%

BioCryst Pharmaceuticals fundamentals help investors to digest information that contributes to BioCryst Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of BioCryst Stock. The fundamental analysis module provides a way to measure BioCryst Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioCryst Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BioCryst Pharmaceuticals Company Annual Yield Analysis

BioCryst Pharmaceuticals' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.

Yield

Income from Security

Current Share Price

More About Annual Yield | All Equity Analysis

BioCryst Annual Yield Driver Correlations

Understanding the fundamental principles of building solid financial models for BioCryst Pharmaceuticals is extremely important. It helps to project a fair market value of BioCryst Stock properly, considering its historical fundamentals such as Annual Yield. Since BioCryst Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioCryst Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioCryst Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Short Term Investments	Common Stock	Current Deferred Revenue	Property Plant Equipment	Net Receivables	Net Tangible Assets	Long Term Debt	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.63	0.71	-0.94	0.91	0.95	1.0	-0.66	0.64	0.93	-0.3	0.87	0.79	-0.8	0.93	0.93	0.85	-0.65	-0.29	0.24	0.93	0.95	0.93
Total Stockholder Equity	-0.63		-0.07	0.58	-0.61	-0.44	-0.61	0.11	0.0	-0.66	0.43	-0.5	-0.22	0.27	-0.38	-0.47	-0.74	0.58	0.05	-0.07	-0.63	-0.65	-0.56
Net Debt	0.71	-0.07		-0.79	0.53	0.88	0.71	-0.69	0.95	0.65	-0.13	0.77	0.89	-0.9	0.9	0.74	0.49	-0.34	-0.33	0.34	0.59	0.6	0.68
Retained Earnings	-0.94	0.58	-0.79		-0.88	-0.95	-0.94	0.52	-0.77	-0.97	0.43	-0.89	-0.78	0.77	-0.91	-0.91	-0.87	0.67	0.36	-0.4	-0.8	-0.84	-0.93
Accounts Payable	0.91	-0.61	0.53	-0.88		0.83	0.92	-0.48	0.5	0.93	-0.34	0.79	0.63	-0.59	0.78	0.87	0.84	-0.6	-0.39	0.31	0.82	0.85	0.91
Total Liab	0.95	-0.44	0.88	-0.95	0.83		0.96	-0.74	0.8	0.89	-0.23	0.88	0.89	-0.9	0.99	0.95	0.76	-0.54	-0.39	0.26	0.87	0.89	0.92
Total Current Assets	1.0	-0.61	0.71	-0.94	0.92	0.96		-0.68	0.63	0.93	-0.27	0.87	0.8	-0.81	0.93	0.95	0.85	-0.64	-0.36	0.24	0.94	0.96	0.95
Short Term Debt	-0.66	0.11	-0.69	0.52	-0.48	-0.74	-0.68		-0.53	-0.43	-0.4	-0.63	-0.84	0.83	-0.8	-0.71	-0.39	0.16	0.29	0.08	-0.76	-0.74	-0.62
Short Term Investments	0.64	0.0	0.95	-0.77	0.5	0.8	0.63	-0.53		0.66	-0.16	0.74	0.8	-0.73	0.8	0.69	0.48	-0.41	-0.29	0.46	0.44	0.46	0.64
Common Stock	0.93	-0.66	0.65	-0.97	0.93	0.89	0.93	-0.43	0.66		-0.4	0.86	0.72	-0.64	0.82	0.89	0.9	-0.74	-0.37	0.46	0.77	0.82	0.94
Current Deferred Revenue	-0.3	0.43	-0.13	0.43	-0.34	-0.23	-0.27	-0.4	-0.16	-0.4		-0.19	0.13	0.09	-0.16	-0.16	-0.33	0.31	0.01	-0.14	-0.16	-0.18	-0.21
Property Plant Equipment	0.87	-0.5	0.77	-0.89	0.79	0.88	0.87	-0.63	0.74	0.86	-0.19		0.8	-0.74	0.86	0.82	0.79	-0.52	-0.27	0.38	0.75	0.77	0.8
Net Receivables	0.79	-0.22	0.89	-0.78	0.63	0.89	0.8	-0.84	0.8	0.72	0.13	0.8		-0.89	0.92	0.82	0.6	-0.42	-0.38	0.34	0.72	0.74	0.81
Net Tangible Assets	-0.8	0.27	-0.9	0.77	-0.59	-0.9	-0.81	0.83	-0.73	-0.64	0.09	-0.74	-0.89		-0.95	-0.81	-0.53	0.29	0.4	-0.08	-0.81	-0.81	-0.75
Long Term Debt	0.93	-0.38	0.9	-0.91	0.78	0.99	0.93	-0.8	0.8	0.82	-0.16	0.86	0.92	-0.95		0.93	0.7	-0.49	-0.39	0.24	0.87	0.88	0.88
Long Term Debt Total	0.93	-0.47	0.74	-0.91	0.87	0.95	0.95	-0.71	0.69	0.89	-0.16	0.82	0.82	-0.81	0.93		0.77	-0.56	-0.54	0.23	0.88	0.9	0.96
Capital Surpluse	0.85	-0.74	0.49	-0.87	0.84	0.76	0.85	-0.39	0.48	0.9	-0.33	0.79	0.6	-0.53	0.7	0.77		-0.73	-0.23	0.37	0.77	0.82	0.87
Deferred Long Term Liab	-0.65	0.58	-0.34	0.67	-0.6	-0.54	-0.64	0.16	-0.41	-0.74	0.31	-0.52	-0.42	0.29	-0.49	-0.56	-0.73		0.15	-0.63	-0.48	-0.53	-0.62
Long Term Investments	-0.29	0.05	-0.33	0.36	-0.39	-0.39	-0.36	0.29	-0.29	-0.37	0.01	-0.27	-0.38	0.4	-0.39	-0.54	-0.23	0.15		-0.25	-0.31	-0.34	-0.49
Short Long Term Debt	0.24	-0.07	0.34	-0.4	0.31	0.26	0.24	0.08	0.46	0.46	-0.14	0.38	0.34	-0.08	0.24	0.23	0.37	-0.63	-0.25		-0.02	0.04	0.32
Net Invested Capital	0.93	-0.63	0.59	-0.8	0.82	0.87	0.94	-0.76	0.44	0.77	-0.16	0.75	0.72	-0.81	0.87	0.88	0.77	-0.48	-0.31	-0.02		1.0	0.87
Net Working Capital	0.95	-0.65	0.6	-0.84	0.85	0.89	0.96	-0.74	0.46	0.82	-0.18	0.77	0.74	-0.81	0.88	0.9	0.82	-0.53	-0.34	0.04	1.0		0.9
Capital Stock	0.93	-0.56	0.68	-0.93	0.91	0.92	0.95	-0.62	0.64	0.94	-0.21	0.8	0.81	-0.75	0.88	0.96	0.87	-0.62	-0.49	0.32	0.87	0.9

Click cells to compare fundamentals

Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.

Competition

Predict BioCryst Pharmaceuticals

In accordance with the recently published financial statements, BioCryst Pharmaceuticals has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Money Managers Now

Money Managers

Screen money managers from public funds and ETFs managed around the world

All Next

Launch Module

BioCryst Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BioCryst Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BioCryst Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

BioCryst Fundamentals

	Return On Equity	-19.25
	Return On Asset	-0.0425
	Profit Margin	(0.30) %
	Operating Margin	0.07 %
	Current Valuation	2.04 B
	Shares Outstanding	207.13 M
	Shares Owned By Insiders	1.15 %
	Shares Owned By Institutions	85.93 %
	Number Of Shares Shorted	19.36 M
	Price To Earning	(7.11) X
	Price To Book	56.59 X
	Price To Sales	3.78 X
	Revenue	331.41 M
	Gross Profit	10.94 M
	EBITDA	(116.33 M)
	Net Income	(226.54 M)
	Cash And Equivalents	417.48 M
	Cash Per Share	2.24 X
	Total Debt	848.71 M
	Debt To Equity	2.40 %
	Current Ratio	5.19 X
	Book Value Per Share	(2.26) X
	Cash Flow From Operations	(95.14 M)
	Short Ratio	7.99 X
	Earnings Per Share	(0.61) X
	Price To Earnings To Growth	(0.28) X
	Target Price	14.82
	Number Of Employees	536
	Beta	1.89
	Market Capitalization	1.56 B
	Total Asset	516.96 M
	Retained Earnings	(1.68 B)
	Working Capital	345.98 M
	Current Asset	65.99 M
	Current Liabilities	64.45 M
	Net Asset	516.96 M

About BioCryst Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BioCryst Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioCryst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioCryst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC